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Abstract 
Background: Progression of chronic kidney disease (CKD) is associated with having a number of complications, 
including thyroid dysfunction. CKD affects the thyroid function by lowering levels of circulating thyroid 
hormones, interfering with hormones binding to protein carriers, disrupting metabolism and elimination of 
thyroid hormones.Aim of the study: We aimed to evaluate and compare thyroid functions among patients on 
chronic hemodialysis (HD) and healthy participants. Methods: This is a cross- sectional study conducted in the 
dialysis unit of Baghdad teaching hospital from ( May 2015 to November 2015). A total of 45 known CKD cases 
(stage 5) older than 18 year were included in the study. Patients with known thyroid disorders, on medications 
affecting thyroid function were excluded from the study. All subjects were clinically euthyroid, they were 
investigated with laboratory tests to determine blood urea, serum creatinine, body mass index, estimated 
glomerular filtration rate (eGFR), thyroid function including: serum triiodothyronine (T3), thyroxin (T4), free T3, 
free T4, and thyroid- stimulating hormone (TSH).Results were compared with the same measurements in 20 
normal subjects as a control group.Results: Of total sample of patients, 22(48.9%) were male, 23(51.1%) were 
female; with mean age of 50.96± 14.26 years. In control group; 12 (60%) were male, 8 (40%) were female with 
mean age of 40.25± 11.86 years. In HD group; we found statistically significant lower mean values of T3 (1.54± 
0.67, p= 0.009), free T3 (2.65± 0.92, p <0.001), and higher frequency of low T3 syndrome in 73. 33% (n=33) vs. 
5% (n= 1) with (p <0.001). Subclinical hypothyroidism was found in control group only, in  20% (n= 4), (p 
<0.001). There was a strong correlation between S. creatinine with free T3, correlation coefficient (- 0.378). In 
patients on HD for equal or more than a year; we found statistically significant lower mean values of T3 (1.07± 
0.23) vs. (1.66± 0.69), (p= 0.016), in spite of significant increase in mean eGFR of (9.00± 4.82) vs. (6.39± 3.08), 
(p= 0.05). There was a statistically significant association between total T4 and presence of DM, (P=  
0.044).Conclusions: We observed that functional thyroid gland disorders are more common among patients on 
chronic hemodialysis compared with healthy subjects, and reveal their link with time on dialysis. Low T3 
syndrome (Euthyroid sick syndrome)is the most frequently thyroid function disorder. 
Keywords: Triiodothyronine, Hemodialysis, Low T3syndrome, Euthyroid sick syndrome. 
 
1. Introduction 
1.1 Thyroid Hormone Metabolism. 
The kidney normally plays an important role in the metabolism, degradation, and excretion of several thyroid 
hormones. All levels of the hypothalamic- pituitary-thyroid axis may be involved, including alterations in 
hormone production, distribution, and excretion. Thus, decline of kidney function is accompanied by a 
characteristic disturbance in thyroid physiology. As a result, abnormalities in thyroid function tests are 
frequently encountered in uremia. 
1 
The kidney normally contributes to the clearance of iodide, primarily by glomerular filtration. Thus, 
iodide excretion is diminished in advanced renal failure, leading sequentially to an elevated plasma inorganic 
iodide concentration and an initial increment in thyroidal iodide uptake.
2 
Increases in total body inorganic iodide can potentially block thyroid hormone production (the Wolff- 
Chaikoff effect). Such a change may explain the slightly higher frequency of goiter and hypothyroidism in 
patients with chronic kidney disease.
3 
 
1.2 Hypothalamic- Pituitary Dysfunction. 
CKD affects the hypothalamus- pituitary-thyroid axis and the peripheral metabolism of thyroid hormone. TSH 
levels are usually normal with an altered circadian rhythm (comprised of TSH bioactivity), the pituitary receptor 
response to TRH is blunted causing a decrease in TSH release and the response of TSH to TRH is delayed 
because of the decreased clearance and the increase of half- life of TSH.
/4 
 
1.3 Subclinical Hypothyroidism.  
Subclinical hypothyroidism is defined as an elevation in serum TSH concentration (normal range 5–10 µIU/mL) 
in conjunction with a normal serum free T4 concentration. With the decline in GFR, the prevalence of 
subclinical hypothyroidism increases consistently. The prevalence of subclinical primary hypothyroidism 
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increased from 7% to 17.9% in individuals whose GFR has decreased from ≥ 90 mL/min to 60 mL/min.
5
 
 
1.4 Low T3Levels. 
Low free T3has emerged as a potent biomarker in ESRD in several studies and represents the main finding of 
non thyroidal illness syndrome (NTIS) in renal disease.
6
 CKD has been known to affect the peripheral 
metabolism of thyroid hormones. Low T3 levels are the most common laboratory finding followed by 
subclinical hypothyroidism in CKD patients. Hyperthyroidism is usually not associated with CKD but has been 
known to accelerate it.
1 
In an issue of the European Journal of Endocrinology, Iglesias P and Diez JJ published in 2009 a 
review article entitled: "Thyroid dysfunction and kidney disease " in which they report that "Serum TSH 
concentrations are usually normal or elevated in CKD. Free and total T3 and T4 concentrations are usually 
normal or low in patients with CKD. This reduction in T3concentrations has been linked to a decrease in the 
peripheral synthesis of T3 from T4. This abnormality is not associated with increased conversion of T4 to the 
metabolically inactive reverse T3 (rT3), since plasma rT3 levels are typically normal. This finding differentiates 
the uremic patient from patients with chronic illness . In the latter setting, the conversion of T4 to T3 is similarly 
reduced, but the generation of rT3 from T4 is enhanced.
7 
The prevalence of the low T3 syndrome is in comparison remarkably high ,being reported in more than 
70% of patients with ESRD. 
8 
Low levels of total T3 may also reflect metabolic acidosis and reduced protein 
binding. 
9
 
Low plasma free T3 levels may also be associated with the presence of the malnutrition-inflammation 
syndrome. The latter is a common chronic condition in dialysis patients associated with markedly increased 
cytokine levels. 
10
 Low T3 levels in CKD may also be due to the decreased clearance of the inflammatory 
cytokines such as TNF-alpha and IL-1. These cytokines inhibit expression of 1 5′- deiodinase that helped convert 
T4 to T3.
 11
The plasma concentration of (TSH) is usually normal in chronic kidney disease. However, the TSH 
response to exogenous thyrotropin- releasing hormone (TRH) is often blunted and delayed, with a prolonged 
time required to return to baseline levels.
12
 Reduced renal clearance may contribute to delayed recovery, since 
TSH and TRH are normally cleared by the kidney. However, the blunted hormone response also suggests 
disordered function at the hypothalamic-pituitary level that may be induced by uremic toxins. When compared to 
normals, patients with CKD have an attenuated rise in TSH levels during the evening hours and the normally 
pulsatile secretion of TSH is smaller in amplitude.
13 
Despite these perturbations, TSH release responds appropriately to changes in the circulating level of 
thyroid hormones. Exogenous T3 lowers TSH levels and can totally suppress the secretory response to 
exogenous TRH. On the other hand, TSH production increases appropriately in response to thyroid ablation. The 
latter response is important clinically, since TSH levels should rise (as in normals) when a uremic patient 
develops hypothyroid.
14 
 
1.5 Effects Of Hemodialysis On Thyroid Function. 
HD is associated with alterations in the concentration of circulating TH, usually to a reduction in serum total and 
free T3 concentrations. Low TH may be a protective adaptation for nitrogen conservation and therefore 
inappropriate TH supplementation can result in excessive protein nitrogen wasting in these patients. HD 
influences the cellular transport of TH. This effect could act as a compensatory mechanism to neutralize the 
thyroid dysfunction in order to maintain euthyroid status.
15 
 
1.6 Clinical Significance 
Low T3 concentrations, although initially thought to be an adaptive response to chronic illness, have been 
associated with all- cause and cardiovascular mortality in uremic patients. As an example, in one study of 210 
hemodialysis patients, low T3 concentrations, particularly if persistent throughout the 38 month study, were 
associated with a higher risk of all- cause and cardiovascular mortality, with hazard ratios of 2.7 and 4.0, 
respectively.
16
 A low T4 but not TSH, was also associated with all- cause and cardiovascular mortality. A 
number of studies have consistently shown that low T3 concentrations are inversely correlated with markers of 
systemic inflammatory response and are an independent predictor of mortality in euthyroid patients with 
ESRD,
17
 and in dialysis populations, having a stronger association with cardiovascular death.
18 
Low T3 has been additionally linked to impaired cardiac function and geometry,
19
 coronary artery 
calcification,
20
 increased intima- media thickness, flow-mediated vasodilatation (FMD),and measures of 
systemic arterial stiffness.
21 
In general, there is substantial clinical overlap between chronic kidney disease and hypothyroidism. In 
addition to low total and plasma free T3 levels, there are a number of symptoms that are common to both 
conditions including cold intolerance, puffy appearance, dry skin, lethargy, fatigability, and constipation. 
Furthermore, the frequency of goiter is markedly increased in end-stage renal disease. Despite these findings, 
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most uremic patients are considered to be euthyroid as evidenced by normal plasma concentrations of TSH and 
free T4, and normal basal metabolic rate and tendonrelaxation time.
22 
Finally the observational nature of the studies reporting these results emphasizes the importance of 
verifying whether uremic patients without primary thyroid dysfunction would benefit from thyroid hormone 
therapy. So far, there is insufficient evidence to recommend routine provision of thyroid hormone replacement in 
CKD with low T3 alone.
23
  
Aim of the study. 
To evaluate and compare thyroid functions among patients on chronic hemodialysis (HD) and healthy 
participants.  
 
2. Patients &Methods. 
2.1 Study design and sample selection 
This is a cross sectional observational study conducted in the dialysis unit of Baghdad Teaching Hospital/ 
medical city in Baghdad from (May 2015 to November 2015). Forty- five patients older than 18 year with CKD 
stage 5 were included in this study; all of them were on regular hemodialysis. 
CKD stage 5 was defined on the basis of National Kidney Foundation guidelines of having an 
estimated glomerular filtration rate (eGFR) < 15 ml/min/1.732 m 
2
 for more than 3 months. The Modification of 
Diet in Renal Disease study (MDRD) equation was used to calculate eGFR.
24 
Patients were dialyzed three times weekly, using a two needle system, low- flux polysulphone dialyzer 
1.6-1.8 m
2
, bicarbonate dialysis solution with dialysate flow 500ml/ min and blood flow rate 300ml/ min. 
Equilibrated Kt/ V was checked monthly and targeted above 1.2, in accordance with K/DOQI guidelines 
(National Kidney Foundation 2006). The dialysis population studied was unselected but patients with severe 
acute complications requiring hospitalization at the time of sampling were not included in the analysis. For the 
sake of the study; hemodialysis patients were divided into two subgroups according to duration of time on 
dialysis: (those < 1y and those ≥ 1y). Twenty healthy volunteers with normal renal function and no previous 
history of thyroid dysfunction were included in this study as a control group.  
 
2.2 Clinical and Laboratory Evaluation 
All patents and control were assessed for possible thyroid dysfunction depending on clinical bases and physical 
examination. 
 
2.3 Exclusion Criteria are: 
1. A family history of goiter or altered thyroid function.  
2. A personal and family history of other organ- specific autoimmune diseases particularly of insulin- dependent 
diabetes, pernicious anemia, vitiligo, and myasthenia gravis.  
3. History of intake of iodine- containing medications, such as amiodarone, lithium carbonate.  
4. History of thyroid surgery or radioactive iodine intake.  
5. Goiter± bruit.  
6. Eye signs (exophthalmos, lid retraction….. etc).  
7. Pretibial myxedema.  
8. Delayed reflexes.  
Pallor, weight loss, palpitation, tremor, neurological symptoms and other manifestations of thyroid 
dysfunction may also occur in uremia, so they are not regarded as signs of possible thyroid dysfunction in the 
study group. All those included in the study underwent estimations of serum total (T3) and serum total (T4) , 
serum (TSH), serum free T3(fT3) and serum free T4(fT4) were performed by (TT3  ELFA kit REF: 30 459), 
(TT4  ELFA kit REF: 41 634), ( TSH  ELFA kit REF: 23 634),(fT3 ELFA kit REF:12 987), (fT4 ELFA kit 
REF:56 342), respectively; these systems provide direct quantitative in vitro administration of L-3,5,3- tri-
iodothyronine (T3), thyroxin (T4), (TSH) in human, serum (fT3) and serum (fT4).  
Serum fT3, fT4 and TSH were measured by using fluorescent immunoassay (VIDAS, biomeriux SA, 
France). As heparin may interfere with competitive assays, blood was drawn just before the start of hemodialysis 
procedure from the inserted dialysis needle, before contact of blood with dialyzer and before heparin 
administration. This ensured that there was an interval of at least 48 hours since the last heparin application.We 
made sure that all patients and control group did not receive furosemide before taking blood samples as it is 
known to influence thyroid function. 
General information regarding age, gender, occupation, and address of the patients and the control 
group were taken. Informationabout duration, etiology of renal failure, type and duration of dialysis, medical 
history of type 2 diabetes mellitus and hypertension were also recorded. Result of basic laboratory investigations 
which include packed cell volume (PCV), blood urea, serum creatinine, fasting blood sugar (FBS), total serum 
protein (TSP) and serum albumin, body mass index (BMI), glomerular filtration rate (GFR) were integrated in 
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this study  
Reference ranges for the biochemical variables of interest are these:  
TSH       (0.25- 5.0 mIU/L) 
T3          (0.92- 2.33 nmol/L) 
Free T3  (4- 8.3 pmol/L) 
T4          (60- 120 nmol/L) 
Free T4  (9- 20 pmol/L). 
 
2.4 Definitions.
25
 
Euthyroidism was defined as normal TSH and T3 and T4.   
Hypothyroidism was defined as TSH > 5 mIU/L and free T4 <9 pmol/L.  
Hyperthyroidism was defined as TSH <0.25 mIU/L and T3 > 2.33 nmol/L or T4 > 120 nmol/L.  
Subclinical hypothyroidism was defined as TSH > 5 mIU/L and normal free T4. 
Euthyroid Sick Syndrome ESS or non thyroidal illness syndrome refers to patients with severe chronic 
illnesses like starvation, sepsis, end stage renal disease, myocardial infarction and others, in whom a decrease in 
serum thyroid hormone levels is observed without any identifiable primary thyroid disease. It is considered when 
free T3< 4 pmol/L and normal TSH.
26 
Severe ESS was definedas free T3< 4 pmol/L, free T4 < 9 and normal TSH.
27,28
 
TSH T4 T3 Interpretation 
High Normal Normal (subclinical) hypothyroidism 
High Low Low or normal clinical Hypothyroidism 
Low 
Normal Normal (subclinical) hyperthyroidism 
Low 
High or normal High or normal Clinical Hyperthyroidism 
Normal 
normal low Low T3 syndrome 
Hypertension is considered if the recorded systolic blood pressure ≥ 140 mmHg and or diastolic blood pressure 
≥ 90 mmHg, or if the patient was on current antihypertensive therapy.
29
 
Diabetes is defined as the use of insulin or glucose- lowering medication on admission, or a diet for diabetes 
documented in medical history.
30 
The study protocol was approved by the scientific council of internal medicine, Iraqi Board of Medical 
specializations, consents were obtained from each patient and control group. 
 
2.5 Statistical analysis. 
All data follow normal distribution (Anderson Darling test was used to test the normality); continuous data were 
presented using mean and standard deviation, while discrete variables were presented using number and their 
percentages. Histogram used to represent the data, while pie gram used to represent the prevalence, and scatter 
plot used for representing linear regression module.Student t test (independent 2 samples) was used to assess the 
statistical significance between means when appropriate. Chi square test (if the table was 2x2 then Fisher exact 
test used instead) used to analyze discrete variables. Linear regression analysis used to test the correlation 
between thyroid panel parameters and eGFR, creatinine, duration of both renal failure and time on dialysis and 
spearman correlation coefficient used to assess the correlation.P. value (2 tailed) was considered to be significant 
if was below 0.05 (level of significance). All data were analyzed using SPSS (20), and figures were drown using 
Microsoft Excel. 
 
3. Results.  
3.1 Basic patient's characteristics. 
As shown in Table 1, total sample of patients was 45, of them 23 (51.1%) were females and 22 (48.9%) were 
males. The control group consists of 20 normal persons, of them 8 (40%) were females and 12 (60%) were males. 
There was no statistically significant difference between two groups regarding gender with (P. value = 0.434). 
Mean age of patients was (50.96± 14.26) years while mean age of controls was 40.25± 11.86 years with 
statistically significant difference (P. value = 0.003). 
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Table 1: Demographic variables in patients and control groups. 
Variables  Patients (n= 45) Control (n= 20) P. value 
No % No % 
Gender  
 
Female 23 51.1 8 40 0.434 
Male 22 48.9 12 60 
Age 
Mean± SD
* 
Mean± SD 0.003 
50.96±14.26 40.25±11.86 
SD
*
, Standard deviation 
 
3.2 Laboratory variables in patients and control groups. 
As shown in Table 2, the mean duration of time with renal failure was 2.7± 1.76 years and mean duration of time 
on dialysis was 7.72± 4.04 months. Mean values of PCV, TSP, albumin, BMI and eGFR were all significantly 
lower in patients compared to normal subjects with (P. value <0.001) and mean values of FBS, urea, creatinine 
were all significantly higher in patients compared to control with (P. value <0.001).  
Table 2: Descriptive data of continuous variables in patients and control groups. 
Variables  Patients (n= 45) Control (n= 20)  P. value 
Mean± SD Mean± SD 
Duration of renal failure (yr) 2.70± 1.76 - - 
Time on dialysis (mo) 7.72± 4.04 - - 
Packed cell volume (PCV) 28.60± 4.28 42.35± 4.86 <0.001 
Fasting blood sugar (FBS, mg/dL) 117.07± 38.40 94.40± 6.98 <0.001 
Blood Urea (mg/dL) 172.27± 47.90 29.45± 5.39 <0.001 
Serum Creatinine (mg/dL) 8.58± 2.79 0.83± 0.11 <0.001 
Total serum protein (TSP, g/L) 62.13± 3.65 71.70± 3.88 <0.001 
Albumin (g/L) 29.69± 2.07 41.10± 3.51 <0.001 
Body mass index/ BMI (kg/ m
2
) 20.66± 2.35 27.97± 2.69 <0.001 
eGFR
*
 (mL/min/1.73m
2
) 6.91± 3.59 101.50±21.01 <0.001 
*
 Estimated glomerular filtration rate    
As shown in Table 3, mean value of TSH in patients was 2.65± 1.53 mIU/l while it wasn3.59± 1.48 
mIU/l in control group with a statistically significant difference with (p value 0.025). Mean values of both total 
and free T3 were lower (1.54± 0.67 and 2.65± 0.92) in patients than healthy participants (1.89± 0.36 and 6.49± 
2.25) with a statistically significant difference (p. values 0.009 and <0.001respectively). While there was no 
statistically significant difference between patients and healthy participants regarding total and free T4 values (p. 
values 0.477 and 0.13 respectively). 
Table 3: Descriptive data of thyroid function test in patients and control. 
Variables  Patients/ Mean± SD* Reference range Control/ Mean± SD  P. value 
 
TSH
**
(mIU/L) 
 
2.65±1.53 
 
0.25-5.0 
 
3.59±1.48 
 
0.025 
T3
§
(nmol/L) 1.54±0.67 0.92-2.33 1.89±0.36 0.009 
Free T3(pmol/L) 2.65±0.92 4.0-8.3 6.49±2.25 <0.001 
T4
†
 (nmol/L) 89.78±19.60 60-120  86.74±13.80 0.477 
Free T4 (pmol/L) 14.51±5.94 9.0-20.0 12.61±3.88 0.13 
*
 Standard deviation,
**
Thyroid stimulating hormone,
§
Ttiiodothyronine, 
†
 Thyroxin   
 As shown in Fig. 1, 42 (93%) patients out of 45 study groupshowed low free T3level and 6 (13%) 
patients showed low free T4level. It is also shown that 40 (90%) patients showed normal level of TSH, and 4 
(9%) showed high TSH. None showed high free T3, while 8 (18%) patients showed high free T4.    
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Figure 1: Distribution of thyroid parameters according to their reference range 
 
3.3 Etiology of CKD in hemodialysis patients. 
Table 4 shows that hypertensive renal disease was the most common underlying cause of CKD fond in 17(37.8%) 
patients, followed by diabetic nephropathy which was present in 16 (35.6%) patients, unidentified cause in 8 
(17.8%), obstructive uropathy in 7 (15.6%) and lupus nephritis in 4 (8.9%) patients. 
Table 4: Etiology of CKD in hemodialysis patients. 
Variables No % 
Hypertensive renal disease 17 37.8 
Diabetic nephropathy 16 35.6 
Unidentified 8 17.8 
Obstructive uropathy 7 15.6 
Lupus nephritis 4 8.9 
 
3.4 Thyroid function test parameters correlation with other variables. 
As shown in table 5, eGFR and serum creatinine shows good correlation with total T3 and free T3 respectively, 
and the correlation between serum creatinine with free T3 was stronger (- 0.378) than the correlation between 
GFR with total T3 (-0.316); both of them inversely correlated as shown in figures 2&3. 
Table 5: linear correlation between GFR and creatinine and thyroid panel. 
Variables eGFR Creatinine 
Correlation coefficient  P value  Correlation coefficient  P value  
TSH -0.107 0.484  0.155 0.308 
T3 total -0.316 0.035 [SD] 0.261 0.083 
T3 free 0.173 0.257 -0.378 0.011 [SD] 
T4 total 0.202 0.184  -0.257 0.089 
T4 free 0.211 0.164 -0.254 0.092 
Pearson correlation was used, p value < 0.05 were significant, SD: significant difference  
 
2015105
4
3
2
1
0
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Figure 2: Scatter plot of total T3 and eGFR showing linear regression line 
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Figure 3: Scatter plot of free T3 and serum creatinine showing linear regression line 
 
3.5 Thyroid dysfunction and duration of time on dialysis. 
As shown in Table 6, patients with duration of time on dialysis more than one year showed lower total T3 values 
compared to those less than a year with statistically significant difference (P. value 0.016) while other thyroid 
parameters didn't show such effect. It is also shown that mean values of B. urea and S. creatinine were 
significantly lower in those on dialysis more than a year with (P. values 0.021 and 0.017 respectively) and mean 
value of eGFR was significantly more after one year of dialysis with (P. value 0.05).  
Table 6: Descriptive data of continuous variables in subgroups of patients.  
Variables  On dialysis < a year On dialysis ≥ a year P. value 
Mean± SD Mean± SD 
TSH(mIU/l) 2.72±1.59 2.35±1.30 0.523 
T3(nmol/l) 1.66±0.69 1.07±0.23 0.016 
Free T3(pmol/l) 2.59±0.84 2.86±1.24 0.442 
T4(nmol/l) 88.69±19.14 94.12±21.96 0.464 
Free T4(pmol/l) 15.05±5.86 12.37±6.10 0.231 
Blood Urea (mg/dL) 180.42±48.87 139.67±26.02 0.021 
Serum Creatinine (mg/dL) 9.07±2.91 6.62±0.70 0.017 
eGFR(mL/min/1.73m
2
) 6.39±3.08 9.00±4.82 0.05 
 
3.6 Rate of thyroid function disorders in patients (total and subgroups). 
In this study, no patient was diagnosed with hypothyroidism or hyperthyroidism. As shown in table 7 and figure 
4, Euthyroid Sick Syndrome (ESS) was found in 33(73.3%) of patients compared with 1(5%) of control. Severe 
ESS was found in7 (15.6%) patients, subclinical hypothyroidism was found only in 4(20%) of control group and 
only 5 (11.1%) patients were euthyroid. All  correlations were statistically significant with (P. value<0.001). 
Table 7: Distribution of study sample according to thyroid status 
Variables   Patients  Control  
P. value 
No Percent % No Percent % 
ESS 33 73.33 1 5 
<0.001 
Euthyroid  5 11.11 15 75 
Severe ESS 7 15.56 0 0 
Subclinical hypothyroidism  0 0 4 20 
Chi square analysis used  
 
 
Figure 4: Rate of thyroid function disorders in hemodialysis patients. 
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3.7 Thyroid parameters in patients according to DM and HTN. 
As shown in table 8, there was no statistically significant difference regarding mean value of  free T3 in diabetic 
and non diabetic patients, the same for HTN, while it was significant between total T4 and presence of DM with 
(P. value 0.044). 
Table 8: Comparison of mean serum thyroid panel in patients divided according to DM and HTN 
Variables 
TSH T3 Free T3 T4 Free T4 
Mean SD Mean SD Mean SD Mean SD Mean SD 
DM 
Negative 2.68 1.31 1.61 .74 2.55 0.99 85.43 17.59 14.06 5.24 
DM 2.59 1.90 1.42 0.51 2.83 0.78 97.66 21.11 15.33 7.15 
P value 0.864 0.35 0.345 0.044 0.497 
HTN 
Negative 2.64 1.35 1.67 0.72 2.55 0.83 87.56 18.39 13.75 4.89 
HTN 2.66 1.83 1.34 0.53 2.81 1.07 93.43 21.51 15.76 7.35 
P value 0.957 0.116 0.366 0.336 0.276 
Independent t test (2 sample), all p value were 2 tailed  
DM: diabetics mellitus, HTN: hypertension  
 
4. Discussion. 
We aimed to assess spectrum of thyroid function disorders in CKD stage (5) patients on chronic hemodialysis. 
The present study identifies thyroid dysfunction as a common disorder in hemodialysis patients. lowT3 syndrome, 
as part of ESS or non- thyroidal illness was found in 42 (93.3%) patients. 
In addition; both total serum T3 and serum freeT3 concentration in patients on chronic HD were 
significantly lower (1.54,and 2.65) than control (1.89 and 6.49) with p-value (0.009 and<0.001) 
respectively .These results confirm earlier observations of several authors that most of patients with chronic 
renal failure have low level of total T3 level.
(31,32,33) 
A study by Lo et al. found that the prevalence of hypothyroidism increased with lower levels of GFR 
(in units of mL/min/1.73 m 
2
 ), occurring in 5.4 % of subjects with GFR greater than or equal to 90, 10.9 % with 
GFR 60–89, 20.4 % with GFR 45–59, 23.0 % with GFR 30–44, and 23.1 % with GFR < 30 (p < 0.001 for trend). 
They reported that 56 % of hypothyroidism cases were subclinical.
34
 
In this study, none of the HD patients showed subclinical hypothyroidism while it was found in20% of 
control group knowing that the prevalence of subclinical hypothyroidism in general population is about 4 to 
8.5%.
35 
This finding is not in consistent with other studies. Saroj et al found that prevalence of subclinical 
hypothyroidism in stage 5 was 43.3 %.
36 
Another study in India among (ESRD) patients, found that the prevalence of subclinical 
hypothyroidism was 24.8 %.
37
  
Another study in hemodialysis patients in Nepal found the combined prevalence of subclinical and 
clinical hypothyroidism in 26.6 % patients.
38
  
Association with hyperglycemia. 
In our study, although there was no significant low T3 among type 2 diabetic patient compared to non diabetic 
but there was significant association between T4 and presence of DM.  
In a recent study in Baghdad, (20%)  of patients with type 2 DM have abnormal thyroid function tests 
compared to (3.33%) of control group.
39
 
Several other studies revealed higher incidence of thyroid dysfunction in diabetic type 2 patients 
comparing to general population. A prevalence of 12.3% was reported among Greek diabetic type 2  patients
40
 
and 16% of Saudi patients with type 2 diabetes were found to have thyroid dysfunction.
41
  
In Jordan, a study reported that thyroid dysfunction was present in 12.5% of type 2 diabetic patients.
 
42
 
In Al Wazzanet al study, sick euthyroid syndrome constituted 15.7% of those with abnormal thyroid 
function in diabetic type 2 patients. 
43 
This can be explained by the fact that in diabetic patients, the nocturnal 
TSH peak is blunted or abolished, and the TSH response to TRH is impaired in addition to impairment in 
peripheral conversion of T4 to T3 that normalizes with improvement in glycemic control. 
In this study, total T3 shows significant inverse good correlation with eGFR; (- 0.316) with P- 
value0.0035 as shown in figure 1, in which total T3 and GFR showing linear regression line and figure 2, in 
which freeT3 and  serum creatinine showing linear regression line, free T3 show good correlation with serum 
creatinine and it was inverse value 0.011. 
This can be explained by the fact that since the kidney contributes to the clearance of iodide, plasma 
iodide retention in CKD favors thyroidal iodide uptake and potentially blocks thyroid hormone production by 
negative feedback mechanism.
 
In addition, systemic acidosis, time on dialysis, markers of endothelial damage, 
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and inflammation from HD are associated with low T3 levels.
 44 
Finally because this study is cross-sectional, the present analysis is limited in its ability to establish 
causal or temporal relationships between thyroid dysfunction and kidney disease.  
 
5. Conclusion. 
Our study showed that functional thyroid gland disorders are more common among patients on chronic 
hemodialysis compared with healthy subjects, and reveal their link with time on dialysis. Low T3 syndrome 
(Euthyroid sick syndrome)is the most frequently thyroid function disorder. 
 
6. Recommendations. 
Clinicians, including nephrologists, need to consider the dangers of thyroid disease and its appropriate treatment 
in conjunction to treating CKD. Future prospective studies are necessary to study the effect of low T3 as a 
prognostic indicator of mortality and to test the causal implication ofT3 in major clinical outcome in CKD. 
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